Speakers

Margie Ackerman, Ph.D., Assistant Professor, Engineering, Dartmouth College
Gregory Adams, Ph.D., CSO, Eleven Biotherapeutics
Adam J. Adler, Ph.D., Professor, Immunology, University of Connecticut
Martha Alexander-Miller, Ph.D., Chair & Professor, Microbiology & Immunology, Wake Forest School of Medicine
Soner Altiok, M.D., Ph.D., CSO, Nilogen Oncosystems
Robert Anders, M.D., Ph.D., Associate Professor, Pathology, Johns Hopkins University
David E. Anderson, Ph.D., CSO, VBI Vaccines
Philip M. Arlen, M.D., President & CEO, Precision Biologics, Inc.
Deepti Aurora-Garg, Ph.D., Director, Companion Diagnostics, Merck
Justin Balko, Pharm.D., Ph.D., Assistant Professor, Medicine & Cancer Biology, Vanderbilt University School of Medicine; Leader of Molecular Oncology, Center for Cancer-Targeted Therapies, Vanderbilt Ingram Cancer Center
Xingfeng Bao, Ph.D., Senior Principal Scientist & Head, Immuno-Oncology, Andover Innovative Medicine Institute, Eisai
Glen N. Barber, Ph.D., Professor & Chair, Cell Biology, University of Miami Miller School of Medicine
Stephen Beers, Ph.D., Associate Professor, Cancer Immunology and Immunotherapy, University of Southampton, United Kingdom
John Bell, Ph.D., Senior Scientist, Center for Innovative Cancer Research, Ottawa Hospital Research Institute
Dennis Benjamin, Ph.D., Senior Vice President, Translational Research, Seattle Genetics, Inc.
Michael Bergmann, M.D., Ph.D., CMO, Vacthera
Jay A. Berzofsky, M.D., Ph.D., Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Allison S. Betof, M.D., Ph.D., Medical Oncology Fellow, Memorial Sloan Kettering Cancer Center
Sihem Bihorel, MS, Pharm.D., Ph.D., Assistant Professor, Department of Pharmaceutics, College of Pharmacy, University of Florida
Pamuk Bilsel, Ph.D., CSO, FluGen
Laurent Boissel, Ph.D., Associate Director, Research & Development, NantKwest, Inc.
Mark Bonyhadi, Ph.D., Head, Research and Academic Affairs, Juno Therapeutics
Darrell R. Borger, Ph.D., Director, Biomarker Laboratory, Massachusetts General Hospital Cancer Center
Marnix Bosch, Ph.D., CTO, Northwest Biotherapeutics
Marcus Bosenberg, M.D., Ph.D., Associate Professor, Dermatology and Pathology, Yale School of Medicine; Co-Leader, Genomics, Genetics and Epigenetics Program, Yale Cancer Center
Adrian Bot, M.D., Ph.D., Vice President, Translational Sciences, Kite Pharma
Zachary Boyd, Ph.D., Companion Diagnostic Program Leader - Tecentriq (Atezolizumab), Genentech
James Brady, Ph.D., Vice President, Technical Applications & Customer Support, MaxCyte
Caroline Breitbach, Ph.D., Vice President, Translational Development, Turnstone Biologics
Joshua Brody, M.D., Director, Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai
Wendy Broom, Ph.D., Associate Director, Innovation and Automation, Genocea Biosciences  
Tullia Bruno, Ph.D., Research Assistant Professor, Immunology, University of Pittsburgh
Lisa H. Butterfield, Ph.D., Professor, Medicine, Surgery and Immunology, University of Pittsburgh
Peter Cameron, Ph.D., Senior Research Scientist, Caribou Biosciences
Martina Canestraro, Ph.D., Senior Scientist, Preclinical Biology, Immunocore, Ltd.
Carmine Carpenito, Ph.D., Principal Scientist, ImClone Systems, Eli Lilly & Co.
Edward Cha, M.D., Ph.D., Associate Medical Director, Cancer Immunotherapy Franchise, Genentech
Brian R. Champion, Ph.D., CSO, Psioxus Therapeutics Ltd.
Michelle Chan Archer, Senior Formulations Specialist, Infectious Disease Research Institute  
Ken Chang, Ph.D., Vice President, Research and Development, Immunomedics
Yvonne Y. Chen, Ph.D., Assistant Professor, Chemical and Biomolecular Engineering, University of California Los Angeles
Zhao Chen, Ph.D., Investigator III, Exploratory Immuno- Oncology, Novartis Institute of Biomedical Research
Kalidip Choudhury, Ph.D., Head, Search and Evaluation, Natera, Inc.
Raphael Clynes, M.D., Ph.D., Vice President, Translational Biology, Xencor 
Mark Cobbold, MRCP, Ph.D., Associate Professor, Massachusetts General Hospital Cancer Center
Jean-Marie Cuillerot, M.D., CMO, Agenus
Rony Dahan, Ph.D., Principal Investigator, Immunology, Weizmann Institute of Science, Israel
Naveen Dakappagari, Ph.D., Senior Director, Protein and Immuno-Oncology Biomarker Development, Navigate Biopharma, a Novartis Company
Asha Das, M.D., Vice President, Clinical Development and Medical Affairs, Tocagen Inc.
Jishnu Das, Ph.D., Postdoctoral Associate, Lauffenburger Lab, Biological Engineering, MIT & Alter Lab, Ragon Institute of MGH, MIT & Harvard
Adil Daud, M.D., Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center
Naomi De Silva, Clinical Site Educator, Clinical Research, Sillajen Biotherapeutics, Inc.
Tara L. Deans, Ph.D., Assistant Professor, Bioengineering, University of Utah
Lelia Delamarre, Ph.D., Group Leader, Cancer Immunotherapy Department, Genentech
Jerrod Denham, Ph.D., Dark Horse Consulting  
Mark Dudley, Ph.D., Senior Vice President, Bioprocessing, Adaptimmune
Jakob Dupont, M.D., MA, Vice President, Global Head Breast & Gyn Cancer Development, Genentech, A Member of the Roche Group
Olivier Elemento, Ph.D., Cancer Systems Biology and Precision Medicine, Weill Cornell Medicine
Justin Eyquem, Ph.D., Research Fellow, Immunology, Memorial Sloan Kettering Cancer Center
Wendy J. Fantl, Ph.D., Assistant Professor, Obstetrics and Gynecology, Stanford University School of Medicine
Steven Fling, Ph.D., Staff Scientist, Vaccine & Infectious Disease, Fred Hutchinson Cancer Research Center; Director, Cancer Immunotherapy Trials Network Immune Monitoring Laboratory  
Agnete Fredriksen, Ph.D., CSO, Vaccibody
Morganna Freeman, DO, FACP, Associate Director, Melanoma & Cutaneous Oncology Program, The Angeles Clinic and Research Institute
Masha Fridkis-Hareli, M.Sc., Ph.D., Founder and President, ATR, LLC  
Matthew Frigault, M.D., Post-Doctoral Fellow, Cellular Immunotherapy, Dana-Farber Cancer Institute
Justin F. Gainor, M.D., Instructor in Medicine, Massachusetts General Hospital
Arnold Gelb, M.D., Senior Director, Companion Diagnostic Development, EMD Serono, Inc.  
Paul Gonzales, Vice President, Non-Clinical Operations, TD2
Paola Grandi, Ph.D., Senior Research Director, Immunology/Virology, Oncorus, Inc.
Benjamin Greenbaum, Ph.D., Assistant Professor, Medicine, Oncological Sciences, and Pathology, Tisch Cancer Institute, Icahn School ofMedicine at Mount Sinai
Farshad Guirakhoo, Ph.D., CSO, GeoVax, Inc.
Yuriy Gusev, Ph.D., Associate Professor, Innovations Center for Biomedical Informatics (ICBI), Georgetown University Medical Center
Abdel Halim, Ph.D., Vice President, Translational Medicine, Biomarkers & Diagnostics, Celldex Therapeutics
Sam Hanash, M.D., Ph.D., McCombs Institute for Cancer Early Detection and Treatment, MD Anderson Cancer Center
Aaron Hansen, M.D., Ph.D., Assistant Professor, Department of Medicine, University of Toronto; Medical Oncologist, Princess Margaret Cancer Center  
Rikke Holmgaard, Ph.D., Senior Research Scientist, Eli Lilly
Shuguang Huang, Ph.D., CSO, Stat4ward LLC
David Huss, Ph.D., Senior Scientist, CAR T Cell Team Lead, Juno Therapeutics
Ella Ioffe, Ph.D., Associate Director, Immune-Oncology, Regeneron Pharmaceuticals
Farren Isaacs, Ph.D., Assistant Professor, Molecular Cellular & Developmental Biology, Systems Biology Institute, Yale University
Vidyashankara Iyer, Ph.D., Scientist, Formulation Sciences, MedImmune
Benjamin Izar, M.D., Ph.D., Medical Oncology Fellow, BIDMC and Center for Cancer Precision Medicine, Dana-Farber Cancer Institute and Broad Institute
Xiaomo Jiang, Ph.D., Investigator, Immuno-Oncology, Novartis Institutes for BioMedical Research
Karin Jooss, CSO, Gritstone Oncology
Pawel Kalinski, M.D., Ph.D., Professor, Oncology, Vice-Chair, Translational Research, Roswell Park Cancer Institute
Megan M. Kaneda, Ph.D., Assistant Project Scientist, University of California, San Diego
David Kaufman, M.D., Ph.D., Executive Director, Translational Immunology & Oncology, Merck Research Laboratories
Howard L. Kaufman, M.D., FACS, Surgical Oncologist, Rutgers Cancer Institute of New Jersey
Tibor Keler, Ph.D., Senior Vice President & CSO, Celldex Therapeutics
Llew Keltner, M.D., Ph.D., CEO, EPISTAT
Sanjay Khare, Ph.D., President, ImmunGene
Takashi K. Kishimoto, Ph.D., CSO, Selecta Biosciences
Harry Kleanthous, Ph.D., Associate Vice President, Head, Research (North America), Sanofi Pasteur
Emilee Knowlton, Ph.D., Immunology Sales Specialist, ProImmune
Keith Knutson, Ph.D., Director, Cancer Vaccine & Immune Therapies Program, Mayo Clinic
Lakshmi Krishnan, Ph.D., Director & Program Leader, Vaccines and Immunotherapeutics, National Research Council, Canada
Klaus Kühlcke, Managing Director, EUFETS GmbH  
Lawrence S. Lamb, Jr., M.N., Ph.D., Professor, Medicine; Director, Cell Therapy Laboratory, University of Alabama at Birmingham
Gary Lee, Ph.D., Director, Genome Editing, Sangamo Therapeutics
Daniel L. Levey, Ph.D., Senior Director, Vaccine Research, Agenus
Bruce Levine, Ph.D., Barbara and Edward Netter Professor, Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine
Louis Levy, Director, Corporate and Business Development, Ultivue
Ofer Levy, M.D., Ph.D., Director, Precision Vaccine Program, Boston Children’s Hospital; Associate Professor, Pediatrics, Harvard Medical School
Daniel Lingwood, Ph.D., Assistant Professor, Medicine, Harvard Medical School
Andrey Loboda, Ph.D., Director, Genetics and Pharmacogenomics, Merck
Shan Lu, M.D., Ph.D., Professor, Medicine, University of Massachusetts Medical School
Jason J. Luke, M.D., FACP, Assistant Professor of Medicine, Melanoma and Developmental Therapeutics Clinics, University of Chicago Medical Center
Sean Mackay, CEO, IsoPlexis
Ravi Madan, M.D., Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute
Stefano Majocchi, Ph.D., Research Scientist, Novimmune SA
Marc Mansour, Ph.D., Chief Business Officer, Vaximm AG
Alex Marson, M.D., Ph.D., Assistant Professor, Microbiology and Immunology, Divisions of Infectious Diseases and Rheumatology, Department of Medicine, UCSF Diabetes Center, University of California San Francisco
Emma Masteller, Ph.D., Senior Director, Immuno-Oncology R&D, Inovio Pharmaceuticals
Douglas G. McNeel, M.D., Ph.D., Professor of Medicine & Director, Solid Tumor Immunology Research, University of Wisconsin Carbone Cancer Center
Sarah McWhirter, Ph.D., Director, STING Program, Aduro Biotech  
Laurence Menard, Ph.D., Senior Research Investigator, Bristol-Myers Squibb
Leonid S. Metelitsa, M.D., Ph.D., Professor, Pediatrics and Immunology, Texas Children’s Cancer Center, Center for Cell & Gene Therapy, Baylor College of Medicine
Jan ter Meulen, M.D., CSO, Immune Design
Paula Miliani de Marval, Ph.D., Research Associate Director, Charles River
Yueh-Ming Loo, Ph.D., Research Assistant Professor, Immunology, University of Washington
Shigeki Miyake-Stoner, Ph.D., Translational Specialist, Molecular and Cell Biology Laboratories, Salk Institute for Biological Studies
Kayvon Modjarrad, M.D., Ph.D., Associate Director, Emerging Infectious Disease Threats, Walter Reed Army Institute of Research
Richard Morgan, Ph.D., Vice President, Immunotherapy, Bluebird Bio
Zachary S. Morris, M.D., Ph.D., Assistant Professor, Human Oncology, University of Wisconsin School of Medicine and Public Health
Matthew Mulvey, Ph.D., CEO, BeneVir Biopharm, Inc.
Hiroshi Nakashima, Ph.D., Instructor, Neuroscience, Brigham and Women’s Hospital
Jaclyn Neely, Ph.D., Senior Research Investigator II, Translational Medicine, IO Biomarker Lead, Bristol-Myers Squibb
Brad Nelson, Ph.D., Co-Director, Immunotherapy Program, British Columbia Cancer Agency, Canada
Fares Nigim, M.D., Massachusetts General Hospital and Harvard Medical School
Jianfang Ning, Ph.D., Instructor, Neurosurgery, Massachusetts General Hospital, Harvard Medical School
Tatiana Novobrantseva, Ph.D., Co-Founder, Head of Research and Development, Verseau Therapeutics
Clodagh O’Shea, Ph.D., Howard Hughes Medical Institute Faculty Scholar; Associate Professor, William Scandling Developmental Chair, Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies
Shane Olwill, Ph.D., Vice President, Head of Development & Immuno-Oncology, Pieris Pharmaceuticals GmbH
Joost Oppenheim, M.D., Senior Investigator, Cancer and Inflammation Program, Head, Cellular Immunology Section, National Cancer Institute, National Institutes of Health
Willem W. Overwijk, Ph.D., Professor, Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center
Mark Paris, Ph.D., Associate Director, Translational Applications, Mitra Biotech
Angie Inkyung Park, Ph.D., Senior Director, Immunotherapy and Stem Cells, OncoMed Pharmaceuticals
Vasiliki Pelekanou, M.D., Ph.D., Associate Research Scientist, Pathology, Yale University School of Medicine
Sari Pesonen, Vice President, Clinical Development, Valo Therapeutics
Nikolai Petrovsky, MBBS, Ph.D., Chairman & Research Director, Vaxine; Professor, Flinders University
Graeme E. Price, Ph.D., Research Microbiologist, Gene Transfer & Immunogenicity, FDA CBER
Peter Pushko, Ph.D., President & CSO, Medigen
Anna Marie Pyle, Ph.D., William Edward Gilbert Professor, Molecular, Cellular & Developmental Biology, Yale University
Yan Qu, Ph.D., Senior Principal Scientist, Pfizer
Samuel D. Rabkin, Ph.D., Professor, Neurosurgery, Massachusetts General Hospital and Harvard Medical School
Rama Rao Amara, Ph.D., Professor, Microbiology and Immunology, Emory University
David A. Reardon, M.D., Professor, Medicine, HarvardMedical School; Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute
Paul Rennert, Ph.D., President and CSO, Aleta Biotherapeutics Inc.
Alexandre Reuben, Ph.D., Postdoctoral Fellow, Surgical Oncology, The University of Texas MD Anderson Cancer Center
Kole T. Roybal, Ph.D., Assistant Professor, Microbiology, Immunology, University of California San Francisco
Christophe Sachse, Ph.D., Site Head Berlin, NMI TT Pharmaservices
Sriram Sathy, Ph.D., Senior Director, Translational Sciences, Jounce Therapeutics
Kurt Schalper, M.D., Ph.D., Assistant Professor, Pathology and Medicine (Medical Oncology), Yale School of Medicine
Dolores J. Schendel, Ph.D., CEO & CSO, Medigene AG
Michael Schickler, Ph.D., CEO, CureTech, Israel
Jonathan D. Schoenfeld, M.D., MPhil, MPH, Assistant Professor, Radiation Oncology, Harvard Medical School
Taylor Schreiber, M.D., Ph.D., CSO, Shattuck Labs, Inc.
Fiona Sharp, Ph.D., Investigator II, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research
John K. Simmons, Ph.D., Director, Translational Science & Diagnostics, Personal Genome Diagnostics, Inc.
Manmohan Singh, Ph.D., Senior Director, Vaccine Formulation Development, Takeda Pharmaceuticals
Anna Slager, Product Development Scientist, Inovio
Susan R. Slovin, M.D., Ph.D., Medical Oncologist, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center
Julianne Smith, Ph.D., Vice President, Translational Science, Cellectis
Elena Spanjaard, Ph.D., Director, Worldwide Research & Development, Regulatory Affairs, Pfizer
David M. Spencer, Ph.D., CSO, Research & Development, Bellicum Therapeutics
Stefani Spranger, Ph.D., Assistant Professor, Biology, MIT
Sasha Stanton, M.D., Ph.D., Acting Instructor, Breast Oncology, University of Washington Tumor Vaccine Group
Zhen Su, M.D., MBA, Vice President & Head of Global Medical Affairs – Oncology, EMD Serono
Gokul Swaminathan, Ph.D., Immuno-Biology Group, Merck Exploratory Science Center, Merck & Co., Inc.
Steven J. Swanson, Ph.D., Senior Vice President, Research, ImmunoCellular Therapeutics, Ltd.
Janis Taube, M.D., Associate Professor, Dermatology & Pathology, Johns Hopkins University
Michael T. Tetzlaff, M.D., Ph.D., Assistant Professor, Department of Pathology, Division of Pathology/ Lab Medicine, The University of Texas MD Anderson Cancer Center
Steve H. Thorne, CSO, Western Oncolytics Ltd.
Talar Tokatlian, Ph.D., Postdoctoral Research Associate, Irvine Lab, Massachusetts Institute of Technology  
Derek A. Wainwright, Ph.D., Assistant Professor, Departments of Neurological Surgery, Microbiology-Immunology, and Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine
Nicola Wallis, Ph.D., Senior Director, Biology, Astex Therapeutics, Ltd., United Kingdom
Steffen Walter, Ph.D., CSO, Immatics US, Inc.
William Watt, Ph.D., President & CEO, EpiThany
Victor Weigman, Ph.D., Director, Translational Genomics, Q² Solutions, a Quintiles Quest Joint Venture
Glen J. Weiss, M.D., MBA, Clinical Associate Professor, University of Arizona College of Medicine, Phoenix 
Ron Weiss, Ph.D., Professor, Biological Engineering, Synthetic Biology Center, Massachusetts Institute of Technology
Theresa Whiteside, Ph.D., Professor, Pathology, Immunology & Otolaryngology, University of Pittsburgh School of Medicine
Jon Wigginton, M.D., CMO, Senior Vice-President, Clinical Development, MacroGenics
Ignacio I. Wistuba, M.D., Department Chair, Department of Translational Molecular Pathology, Division of Pathology & Lab Medicine, The University of Texas MD Anderson Cancer Center
K. Dane Wittrup, Ph.D., Carbon P. Dubbs Professor, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology
Rich Woessner, Ph.D., Principal Scientist, IMED Oncology, AstraZeneca Pharmaceuticals
Wilson Wong, Ph.D., Assistant Professor, Biomedical Engineering, Boston University
Jennifer Wu, Ph.D., Professor, Feinberg School of Medicine; Director, Cancer Immunotherapy Program, Robert Lurie Comprehensive Cancer Center, Northwestern University 
Masahide Yano, Ph.D., Research Scientist, Center for Drug Evaluation and Research, FDA
Xingxing Zang, Ph.D., Associate Professor, Microbiology and Immunology & Medicine, Albert Einstein College of Medicine
Litao Zhang, Ph.D., Vice President, Leads Discovery and Optimization, Bristol-Myers Squibb
Theresa Zhang, Ph.D., Vice President, Personalized Cancer Vaccines, Genocea Biosciences Gergana Zlateva, Ph.D., Vice President, Payer Insights and Access, Oncology, Pfizer